MARKET

PLUR

PLUR

PLURILOCK SEC INC
NASDAQ
1.070
-0.065
-5.76%
After Hours: 1.150 +0.08 +7.48% 18:14 02/03 EST
OPEN
1.100
PREV CLOSE
1.135
HIGH
1.140
LOW
1.070
VOLUME
12.12K
TURNOVER
0
52 WEEK HIGH
2.210
52 WEEK LOW
0.6500
MARKET CAP
34.94M
P/E (TTM)
-0.9545
1D
5D
1M
3M
1Y
5Y
Pluri Inc (Pluristem Therapeutics) Holds No Hope For The Weak
Seeking Alpha · 01/23 18:41
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 01/13 21:31
Pluri Prices $8.2M Private Placement Offerings Priced At-The-Market Under Nasdaq Rules
Benzinga · 12/15/2022 21:07
Pluri to Present and Participate in Upcoming Conferences
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three upcoming confere...
GlobeNewswire · 10/31/2022 12:00
Pluri Received Letter From Nasdaq Dated October 12 That Co. No Longer Satisfies Nasdaq Listing Rule 5450(A)
October 12, 2022, Pluri Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) advising the Company that for 30 consecutive trading
Benzinga · 10/13/2022 20:53
BRIEF-Pluri Issues Letter To Shareholders Announcing New Tech Collaboration
BRIEF-Pluri Issues Letter To Shareholders Announcing New Tech Collaboration
Reuters · 09/29/2022 11:22
Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates
New company strategy will reduce cash burn by approximately 30%, with $56M in cash on consolidated balance sheetLeading European manufacturer of active pharmaceutical ingredients (APIs) to use Pluri’s 3D cell expansion technology, which aims to revolutioni...
GlobeNewswire · 09/29/2022 11:00
Earnings week ahead: Micron, Nike, Bed Bath & Beyond, CarMax and more
For the final week of September, a number of high-profile earnings reports are expected. Quarterly results are slated from a wide variety of players across the semiconductor, packaged food, restaurant, retail and leisure industries. Nike (...
Seekingalpha · 09/23/2022 16:27
More
About PLUR
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Webull offers kinds of Pluri Inc stock information, including NASDAQ:PLUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLUR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLUR stock methods without spending real money on the virtual paper trading platform.